RAPT Therapeutics Inc. announced key management changes following its 2025 annual meeting of stockholders. The company's stockholders approved the 2025 Equity Incentive Plan and the amendment and restatement of the 2019 Employee Stock Purchase Plan, which both became effective immediately. Additionally, it was decided that stockholder advisory votes on executive compensation will occur annually.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.